Phibro Animal Health (PAHC) Q4 2024 earnings summary

Executive summary

• Q4 consolidated net sales grew 7% year-over-year to $273.2M, led by 8% Animal Health growth and strong vaccine and MFA performance.

• Full-year consolidated net sales rose 4% to $1.017 billion; Animal Health up 7%, Mineral Nutrition flat, Performance Products down 10%.

• Q4 adjusted EBITDA up 3% to $33.4M; adjusted net income and EPS up 10%.

• GAAP net income and EPS declined sharply due to foreign currency losses, higher SG&A, and tax items, partially offset by gross profit gains.

• Announced $350M Zoetis MFA acquisition, expected to close in Q4 2024.

Financial highlights

• Q4 consolidated net sales: $273.2M, up 7% year-over-year; Q4 adjusted EBITDA: $33.4M, up 3%.

• Q4 adjusted net income: $16.7M, up 10%; diluted EPS: $0.41.

• Full-year adjusted EBITDA: $111.2M, down 1%; adjusted net income: $48.4M, down 1%.

• Free cash flow for the year: $46M; cash and equivalents: $115M; total debt: $489M.

• Q4 gross profit up 14% to $87.2M; gross margin improved 180 bps to 31.9%.

Outlook and guidance

• FY2025 guidance: net sales $1.04–$1.09B (2–7% growth), adjusted EBITDA $118–$126M (6–13% growth), adjusted net income $50–$56M (3–15% growth), adjusted EPS $1.22–$1.37.

• Guidance excludes pending Zoetis MFA acquisition; update to be provided post-close.

• Phibro Forward initiative to drive incremental EBITDA and margin growth, with one-time consulting costs included in GAAP guidance.

• Anticipates continued Animal Health growth and recovery in Mineral Nutrition and Performance Products.